The new accounting date is to September 2025, changed from March, so the next full audited report is for 18 months to be announced in January 2026. The trading-update on 4 November last week included a 12-month contribution from ABISS which was acquired on 9 September 2024. RUA stated its growth strategy is to increase the scale of the medical device and component manufacturing, reduce customer concentration, develop royalties from Biomaterials, and break-even. RUA Life Sciences operates in the ....